SELLAS Life Sciences Group, Inc. (SLS) stock
SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.86−0.17 (-2.12%)
Close on Nov 13, 2026Market cap $1.59BP/E –Yield –
SELLAS Life Sciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
SELLAS Life Sciences's ebitda for the twelve months ending Sep 30, 2017 was -$5.73M. For fiscal 2016 it was -$15.99M. The highest annual figure on record is -$12.32M in fiscal 2011.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | -$15.99M | – |
| FY2015 | Dec 31, 2015 | -$34.11M | – |
| FY2014 | Dec 31, 2014 | -$43.81M | – |
| FY2013 | Dec 31, 2013 | -$28.20M | – |
| FY2012 | Dec 31, 2012 | -$21.15M | – |
| FY2011 | Dec 31, 2011 | -$12.32M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2017 | Sep 30, 2017 | -$4.44M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.89M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.06M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.65M | – |
See a number that looks wrong?